A systematic review of the effect of semaglutide on lean mass: insights from clinical trials
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Semaglutide, a glucagon-like peptide-1 receptor agonist, is associated with significant weight loss, yet its impact on lean body mass remains insufficiently understood. This review investigates the effect of semaglutide on lean mass in the context of obesity management. METHODOLOGY: This study investigates through different databases (PubMed, Elsevier, and Google Scholar) from 2016 for randomized control trials (RCTs) or observational studies that assessed the use of semaglutide in overweight or obese patients, regardless of whether they have type 2 diabetes or not. The studies compared semaglutide to a placebo or alternative medications. RESULTS: Six studies with 1,541 overweight or obese adults were included, and significant weight reductions were observed primarily due to fat mass loss. While the lean mass remained stable in some cases, notable reductions ranging from almost 0% to 40% of total weight reduction were observed in others. Noteworthy decreases in lean mass were particularly evident in larger trials, yet the proportion of lean mass relative to total body mass increased, suggesting a positive overall outcome. CONCLUSION: Semaglutide displays potential for weight loss primarily through fat mass reduction. However, concerns arise from notable reductions in lean mass, especially in trials with a larger number of patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP‐1‐induced weight loss is frequently accompanied by loss of lean muscle mass, often more severe than that observed with caloric restriction alone [12, 40].”
From Muscle Loss in Obesity Therapy as a Therapeutic Target: Trial Design and Endpoints for Regulatory Discussions (2025) · cites this paper as [40]
In the citing paper
“In a clinical study with women, supplementation with 30 g of WP per day for 4 weeks resulted in greater reductions in body weight and fat mass, together with an increase in fat-free mass [267]”
From Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review (2025) · cites this paper as [267]
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 1×
“While the overall reduction in weight was primarily attributed to the loss of fat mass, noteworthy reductions in lean mass were observed in the larger randomized controlled trials conducted by Wilding et al. [23] and McCrimmon et al. [25].”
ResultObesity: global epidemiology and pathogenesis
Blüher, M. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0176-8 · Cited by 5,126 · cited 1×
“So far, efforts aiming to prevent and treat obesity have shown limited effectiveness in the long-term run [6].”
BackgroundProspective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Greenhalgh, T., & Peacock, R. (2005) · BMJ · doi:10.1136/bmj.38636.593461.68 · Cited by 2,045 · cited 1×
“All references from the selected studies were retrieved and manually reviewed according to the snowball effect [22].”
MethodThe underappreciated role of muscle in health and disease
Wolfe, R. R. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/84.3.475 · Cited by 1,537
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129 · cited 1×
“More specifically, semaglutide (Figure 1), a glucagon-like peptide-1 receptor agonist (GLP-1 RA), administered on a weekly basis, has exhibited impressive results in enhancing glucose control and inducing significant reductions in body weight [9].”
BackgroundShuster, A., Patlas, M., Pinthus, J. H., & Mourtzakis, M. (2012) · The British Journal of Radiology · doi:10.1259/bjr/38447238 · Cited by 918
The link between abdominal obesity, metabolic syndrome and cardiovascular disease
Ritchie, S. A., & Connell, J. M. C. (2007) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2006.07.005 · Cited by 726
Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717 · cited 1×
“These findings indicate the importance of delving into the mechanistic pathways of GLP-1 receptor agonists like semaglutide, to better understand their effects on body composition [33].”
Background
Cited by
Spotlight on the Mechanism of Action of Semaglutide
Papakonstantinou, I. P., Tsioufis, K. P., & Katsi, V. K. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46120872 · Cited by 102
Skeletal muscle and MASLD: Mechanistic and clinical insights
Marjot, T., Armstrong, M. J., & Stine, J. G. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000711 · Cited by 82
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58
“GLP-1 medications can cause a range of side effects related to the gastrointestinal system as well as changes in muscle mass and effects on the appearance of the face and loss of hair (Figure 2). been further corroborated by other investigators [181].”
Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study
Ditzenberger, G. L., Lake, J. E., Kitch, D. W., Kantor, A., Muthupillai, R., Moser, C., Belaunzaran-Zamudio, P. F., Brown, T. T., Corey, K., Landay, A. L., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciae384 · Cited by 44
Misrepresentation of semaglutide in social media
Propfe, L. E., & Seifert, R. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04403-5 · Cited by 54
Metadata
- Authors
- Bikou, A., Dermiki-Gkana, F., Penteris, M., Constantinides, T. K., & Kontogiorgis, C.
- Affiliations
- Democritus University of Thrace (GR)
- Laboratory of Hygiene and Environmental Protection, Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece
- Corresponding author
- Kontogiorgis, Christos
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2024-03-23
- Volume
- 25
- Issue
- 5
- Pages
- 611-619
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W4394874190
- Cited by
- 97
- References
- 51
- Citations by year
- 2026: 47 · 2025: 35 · 2024: 14
- FWCI
- 6.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- semaglutide, lean body mass, fat loss, weight loss, obesity, overweight, GLP-1 receptor agonists, type 2 diabetes, body composition
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Humans, Obesity, Weight Loss, Randomized Controlled Trials as Topic, Anti-Obesity Agents, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. https://app.cochat.ai/papers/10.1080/14656566.2024.2343092
- The paper
- Bikou, A., Dermiki-Gkana, F., Penteris, M., Constantinides, T. K., & Kontogiorgis, C. (2024). A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2024.2343092
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.